In this context, an anti-CCN2 antibody (FG-3019) is being tested in several clinical trials related to diseases with elevated CCN2 levels, such as Duchenne muscular dystrophy (NCT02606136), pancreatic adenocarcinoma (NCT04229004), and pulmonary fibrosis (NCT03955146), all of which are associated with fibrotic processes. The gene discussed is CCN2; the disease is pancreatic adenocarcinoma.